MDACC Study No:2006-0075 ( NCT No: NCT00972101)
Title:Infusion of Expanded Cord Blood T cells following Cord Blood Transplantation
Principal Investigator:Laura L. Worth
Treatment Agent:Etoposide; Expanded Cord Blood T Cells; Filgrastim; Fludarabine; Melphalan; Mycophenolate Mofetil; Rituximab; Tacrolimus; Thiotepa; Thymoglobulin; Total Body Irradiation
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if treating umbilical cord
blood with growth factors before a transplant can help to improve the body's
ability to accept the cord blood transplants.
Hide details for General InformationGeneral Information

Disease Group:Blood And Marrow Transplantation; Leukemia; Lymphoma; Pediatrics
Phase of Study:Phase I
Treatment Agents:Etoposide
Expanded Cord Blood T Cells
Mycophenolate Mofetil
Total Body Irradiation
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Initial phase of treatment: 30 - 50 days in the inpatient unit.

Patients will be followed out patient after discharge. Readmission may be
Patients are expected to remain in Houston for 4 - 6 months.
Supported By:N/A
Return Visit:After the first 100 days (+/-3 days), every 3 months (+/-1 week) during the
first year, and then annually (+/-1 week) while the subject is on the study.
Patients will be considered on study for up to 5 yrs. unless a criterion for
removal is met.
Home Care:If needed, parental nutrition, antibiotic, IV fluids and antiemetics may be
given at home.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Laura L. Worth
For Clinical Trial Enrollment:713-792-6620
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults